Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02556463
Title A Study of MEDI9197 in Subjects With Solid Tumors or CTCL and in Combination With Durvalumab and Palliative Radiation in Subjects With Solid Tumors
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors MedImmune LLC

Advanced Solid Tumor

primary cutaneous T-cell non-Hodgkin lymphoma



Durvalumab + MEDI9197

Age Groups: senior | adult
Covered Countries USA | FRA | CAN

No variant requirements are available.